Total Payments
$53,399
2024 Payments
$24,167
Companies
10
Transactions
77
Medicare Patients
918
Medicare Billing
$127,898
Payment Breakdown by Category
Consulting$41,770 (78.2%)
Travel$7,314 (13.7%)
Other$1,750 (3.3%)
Food & Beverage$1,532 (2.9%)
Research$1,033 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $41,770 | 18 | 78.2% |
| Travel and Lodging | $7,314 | 15 | 13.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,750 | 1 | 3.3% |
| Food and Beverage | $1,532 | 35 | 2.9% |
| Unspecified | $1,033 | 8 | 1.9% |
Payments by Type
General
$52,366
69 transactions
Research
$1,033
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $26,845 | 40 | $0 (2024) |
| Eli Lilly and Company | $7,866 | 8 | $0 (2023) |
| Axsome Therapeutics, Inc. | $7,400 | 7 | $0 (2024) |
| Biogen, Inc. | $6,032 | 13 | $0 (2024) |
| Genentech, Inc. | $2,070 | 1 | $0 (2022) |
| Allergan Inc. | $1,811 | 3 | $0 (2017) |
| Alnylam Pharmaceuticals Inc. | $660.00 | 1 | $0 (2022) |
| Becton, Dickinson and Company | $623.33 | 1 | $0 (2021) |
| Lilly USA, LLC | $65.43 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $25.45 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,167 | 26 | Eisai Inc. ($16,671) |
| 2023 | $10,186 | 12 | Eisai Inc. ($4,054) |
| 2022 | $10,573 | 22 | EISAI INC. ($6,121) |
| 2021 | $4,523 | 5 | Eli Lilly and Company ($3,900) |
| 2020 | $1,130 | 1 | Biogen, Inc. ($1,130) |
| 2019 | $25.45 | 1 | Novartis Pharmaceuticals Corporation ($25.45) |
| 2018 | $982.56 | 7 | Biogen, Inc. ($982.56) |
| 2017 | $1,811 | 3 | Allergan Inc. ($1,811) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/31/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $65.99 | General |
| 10/29/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $3,510.00 | General |
| Category: Neurology | ||||||
| 10/29/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $585.00 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $34.00 | General |
| Category: Neurology | ||||||
| 10/11/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Neurology | ||||||
| 07/31/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: Neuroscience | ||||||
| 07/29/2024 | Eisai Inc. | — | Food and Beverage | In-kind items and services | $26.97 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,719.00 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $417.75 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $93.59 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $63.84 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $49.46 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $29.26 | General |
| 07/27/2024 | Axsome Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $26.60 | General |
| 06/04/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $292.50 | General |
| Category: Neurology | ||||||
| 02/21/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $7,020.00 | General |
| Category: Neurology | ||||||
| 02/21/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $3,510.00 | General |
| Category: Neurology | ||||||
| 02/21/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $349.39 | General |
| Category: Neurology | ||||||
| 02/21/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $73.50 | General |
| Category: Neurology | ||||||
| 01/27/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $577.03 | General |
| Category: Neurology | ||||||
| 01/27/2024 | Eisai Inc. | Leqembi (Drug) | Travel and Lodging | Cash or cash equivalent | $454.95 | General |
| Category: Neurology | ||||||
| 01/27/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Neurology | ||||||
| 01/27/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $982.56 | 7 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 268 | 328 | $221,229 | $40,591 |
| 2022 | 3 | 194 | 244 | $157,612 | $28,073 |
| 2021 | 4 | 213 | 273 | $172,977 | $31,900 |
| 2020 | 4 | 243 | 293 | $173,025 | $27,334 |
Total Patients
918
Total Services
1,138
Medicare Billing
$127,898
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 105 | 130 | $96,850 | $20,036 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 98 | 128 | $70,400 | $12,966 | 18.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $31,904 | $4,239 | 13.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 25 | $12,975 | $1,803 | 13.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 13 | $9,100 | $1,548 | 17.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 123 | 164 | $90,200 | $16,818 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 40 | 49 | $36,505 | $7,080 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $30,907 | $4,175 | 13.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 131 | 177 | $97,350 | $18,899 | 19.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 48 | 60 | $44,700 | $8,772 | 19.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $20,202 | $2,800 | 13.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 15 | $10,725 | $1,429 | 13.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 138 | 177 | $97,350 | $15,379 | 15.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 52 | 60 | $44,700 | $7,692 | 17.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 21 | 21 | $17,850 | $2,225 | 12.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 32 | 35 | $13,125 | $2,039 | 15.5% |
About Dr. Martin Sadowski, M.D
Dr. Martin Sadowski, M.D is a Neurology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1407840127.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Sadowski, M.D has received a total of $53,399 in payments from pharmaceutical and medical device companies, with $24,167 received in 2024. These payments were reported across 77 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($41,770).
As a Medicare-enrolled provider, Sadowski has provided services to 918 Medicare beneficiaries, totaling 1,138 services with total Medicare billing of $127,898. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location New York, NY
- Active Since 09/08/2005
- Last Updated 03/26/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407840127
Products in Payments
- Leqembi (Drug) $20,698
- NAMZARIC (Drug) $1,811
- ADUHELM (Biological) $109.65
- EMGALITY (Drug) $35.00
- KISUNLA (Drug) $30.43
- API015 (Drug) $25.45
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in New York
Dr. Stephen Krieger, Md, MD
Neurology — Payments: $1.6M
Neurology $1.6M
Dr. David Dodick, M.d, M.D
Neurology — Payments: $765,174
Neurology $765,174
Dr. David Simpson, M.d, M.D
Neurology — Payments: $638,492
Neurology $638,492
Steven Wolf, Md, MD
Neurology — Payments: $585,108
Neurology $585,108
Dr. Alexander Shtilbans, Md, Ph.d, MD, PH.D
Neurology — Payments: $550,165
Neurology $550,165
Dr. Fred Lublin, M.d, M.D
Neurology — Payments: $549,390
Neurology $549,390